Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Jennifer, Yen"'
Autor:
Chin-Shern Lau, Ya Li Liang, Soon Kieng Phua, Gillian Murtagh, Imo E. Hoefer, Ron H. Stokwielder, Milica Kosevich, Jennifer Yen, Jaganathan Sickan, Christos Varounis, Tar-Choon Aw
Publikováno v:
Diagnostics, Vol 12, Iss 5, p 1172 (2022)
Background: We evaluated the performance of the Abbott N-terminal pro-brain natriuretic peptide (NT-proBNP) assay against the Roche NT-proBNP immunoassay across two sites. Methods: Precision, linearity, and sensitivity studies were performed. A combi
Externí odkaz:
https://doaj.org/article/dab34588f7954cdc897407f6d5b8e1e1
Publikováno v:
Journal of Epidemiology and Global Health, Vol 9, Iss 4 (2019)
Truck drivers constitute a highly vulnerable population with very limited opportunities for healthy foods and healthy eating choices. This cross-sectional study assessed the utility of the Theory of Planned Behavior (TPB) in understanding and predict
Externí odkaz:
https://doaj.org/article/db648197305949b887694e998a5ee473
Autor:
Oliver Gautschi, Jennifer Yen, Stephen Fairclough, David R. Trevarthen, Vivek Subbiah, Thomas E. Stinchcombe, Jonathan W. Riess, Richard B. Lanman, Victoria M. Raymond, Michael Oh, Wade T. Iams, Robert C. Doebele, Young Kwang Chae, Karen L. Reckamp, Thereasa A. Rich
Purpose:RET is an emerging oncogenic target showing promise in phase I/II clinical trials. An understudied aspect of RET-driven cancers is the extent to which co-occurring genomic alterations exist and how they may impact prognosis or therapeutic res
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00f02a2c5e71cea090aca52c199c4a25
https://doi.org/10.1158/1078-0432.c.6528704.v1
https://doi.org/10.1158/1078-0432.c.6528704.v1
Autor:
Oliver Gautschi, Jennifer Yen, Stephen Fairclough, David R. Trevarthen, Vivek Subbiah, Thomas E. Stinchcombe, Jonathan W. Riess, Richard B. Lanman, Victoria M. Raymond, Michael Oh, Wade T. Iams, Robert C. Doebele, Young Kwang Chae, Karen L. Reckamp, Thereasa A. Rich
Supplementary Data
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::219b349ee983496e0be3c30ee367003c
https://doi.org/10.1158/1078-0432.22474163
https://doi.org/10.1158/1078-0432.22474163
Autor:
Massimo Cristofanilli, Aditya Bardia, Richard B. Lanman, Stephen R. Fairclough, Victoria M. Raymond, Benjamin L. Maughan, Neeraj Agarwal, Benjamin B. Bridges, Barbara A. Parker, Adam M. Brufsky, Alice C. Fan, Benedito A. Carneiro, Sandip P. Patel, Mohammad Amin Nezami, Michael B. Lilly, Tracy Nance, Aaron Hardin, Jennifer Yen, Oliver Sartor, Thereasa A. Rich, Neelima Vidula
Supplemental Table 1
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::213533586056e2ed5d7de6952a3e5aaf
https://doi.org/10.1158/1078-0432.22478339.v1
https://doi.org/10.1158/1078-0432.22478339.v1
Autor:
Massimo Cristofanilli, Aditya Bardia, Richard B. Lanman, Stephen R. Fairclough, Victoria M. Raymond, Benjamin L. Maughan, Neeraj Agarwal, Benjamin B. Bridges, Barbara A. Parker, Adam M. Brufsky, Alice C. Fan, Benedito A. Carneiro, Sandip P. Patel, Mohammad Amin Nezami, Michael B. Lilly, Tracy Nance, Aaron Hardin, Jennifer Yen, Oliver Sartor, Thereasa A. Rich, Neelima Vidula
Purpose:PARP inhibitors (PARPi) are efficacious in multiple cancers harboring germline (and possibly somatic) BRCA1/2 mutations. Acquired reversions can restore BRCA1/2 function, causing resistance to PARPi and/or platinum-based chemotherapy. The opt
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32427315b0f6dd8f14f80ddf82eba7e3
https://doi.org/10.1158/1078-0432.c.6529925.v1
https://doi.org/10.1158/1078-0432.c.6529925.v1
Autor:
Jennifer Yen, Leylah Drusbosky, Caroline Weipert, Nicole Zhang, David Hanna, Catalin Barbacioru, Hao Wang, Alex Artyomenko, Arielle Yablonovitch, Yu Fu, Aaron Hardin, Nagesh Alla, Robert Foley, Max Maligska, Bhargavi Panchangam, Phil Yen, Jane Meisel, Neelima Vidula, Massimo Cristofanilli, Jeremy Force, Michael Dorschner, Martina Lefterova, Elena Helman, Becky Nagy, Darya Chudova, AmirAli Talasaz
Publikováno v:
Cancer Research. 82:P5-13
Background: Inactivating HRR gene mutations can lead to HRR deficiency (HRD) and predict response to PARPi therapy in patients with breast cancer. Copy number loss and large genomic rearrangements (LGR) can result in HRD but are challenging to detect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::74c5237ce3735f83088c361bd3f5bfe6
https://doi.org/10.1158/1538-7445.sabcs21-p5-13-29
https://doi.org/10.1158/1538-7445.sabcs21-p5-13-29
Autor:
Jennifer Yen, Justin Stebbing, Li Mao, Jian Cui, Yong-Chang Zhang, Xianghua Ye, Giovanni Selvaggi, Kui Xiao, Ling Peng
Publikováno v:
OncoTargets and therapy
Background Alectinib is approved for the treatment of advanced non-small-cell lung cancer (NSCLC) harboring ALK rearrangements. Although generally well tolerated, alectinib can cause serious or life-threatening side effects. Case Presentation Here, w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e5fbf2cf9ded0902ad6b6b594e39785a
http://europepmc.org/articles/PMC8164872
http://europepmc.org/articles/PMC8164872
Autor:
Jennifer Yen, Yu Fu, Jeff Werbin, Katie Quinn, Robert Foley, Minh Trahn, Carin Espenschied, Scott Higdon, Brett Kennedy, Han-Yu Chuang
Publikováno v:
Cancer Research. 83:3135-3135
Background: Liquid biopsy has been established as a powerful, non-invasive means to profile tumors in and identify clinically relevant variants. However, the presence of clonal hematopoiesis (CH) variants, or biological noise, due to aging or therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0aaf7b189bd220fb68f76005b4860420
https://doi.org/10.1158/1538-7445.am2023-3135
https://doi.org/10.1158/1538-7445.am2023-3135
Autor:
Elizabeth Harvey-Jones, Maya Raghunandan, Luisa Robbez-Masson, Alaguthurai Thanussuyah, Roberta Liccardo, Arielle Yablonovitch, Mingyang Cai, Leylah Drusbosky, Michael Dorschner, Lorena Magraner Pardo, Rebecca Marlow, Asha Konde, Jennifer Trendell, John Alexander, Syed Haider, Chris Starling, Ioannis Roxanis, Jennifer Yen, Stephen J. Pettitt, Christopher J. Lord, Andrew N. Tutt
Publikováno v:
Cancer Research. 83:6094-6094
Background: Assessing how clinical resistance to PARP inhibitors develops has been challenging, due to the lack of coverage of potential resistance genes in sequencing panels and biopsies being subject to spatial heterogeneity. We studied the develop
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c53ea98789a8520482ad96af4b350c7a
https://doi.org/10.1158/1538-7445.am2023-6094
https://doi.org/10.1158/1538-7445.am2023-6094